MTI 2022 Outlook: The Post-COVID Mantra For Medtechs: Prioritize, Optimize And Modernize
Industry leaders back at the wheel are driving health care transformation
Executive Summary
Medtech’s resilience and flexibility have been clear to see during the COVID-19 pandemic. In this forward-looking view for 2022, CEOs from some of the leading global medtechs share their perspectives on the present and the future, from company and health care system standpoints.
You may also be interested in...
MTI 100 Review: Medtechs Drive To Keep The Status Quo In A Year Like No Other
The performances of the leading medtechs in the first year of the COVID pandemic were impossible to compare and certainly unrepresentative of normal business cycles and competitive activity. Elective care was largely put on hold and emergency needs boosted exceptional demand for certain product types. More than anything else, 2020 tested management's planning skills.
Medtronic Looks Beyond The World Of Doctors And Devices In New Approach To Markets
Health warning to global medtechs: The world’s largest medical device company is taking steps to strengthen key account management, retain its market share hold and set up new health care partnerships.
UK Life Sciences Cautiously Upbeat For Investment Year Ahead – BioWales 2024
Favorable UK biopharma investment trends have been reported by the BioIndustry Association, but can medtech and healthtech share in the positivity? A roundtable at the BioWales in London 2024 event framed the outlook for non-pharma players.